# Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

> **NCT03206203** · PHASE2 · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 106 (actual)

## Conditions studied

- Triple Negative Breast Cancer
- Stage IV Breast Cancer
- HER2 Negative
- Invasive Breast Cancer

## Interventions

- **DRUG:** Atezolizumab
- **DRUG:** Carboplatin
- **OTHER:** Laboratory Biomarker
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT03206203
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-29
- **Primary completion:** 2022-11-30
- **Final completion:** 2023-10-04
- **Target enrollment:** 106 (ACTUAL)
- **Last updated:** 2024-12-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03206203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03206203, "Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03206203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*